Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y8UP
|
|||
| Former ID |
DNC014645
|
|||
| Drug Name |
2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one
|
|||
| Synonyms |
9008-02-0; CHEMBL130391
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H10N2O2
|
|||
| Canonical SMILES |
CC1=NC2=C(C=C1)C(=O)C=C(N2)C3=CC=CO3
|
|||
| InChI |
1S/C13H10N2O2/c1-8-4-5-9-11(16)7-10(15-13(9)14-8)12-3-2-6-17-12/h2-7H,1H3,(H,14,15,16)
|
|||
| InChIKey |
INGWEZCOABYORO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 9008-02-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin (TUB) | Target Info | Inhibitor | [1] |
| Tubulin beta (TUBB) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.